Table 5.
Univariate linear regression analysis of anti-Parkinson's disease drugs for serum butyrylcholinesterase activity in PD patient.
| Variable | Patient percentage | Beta value | P value |
|---|---|---|---|
| Total patients | 76 (100%) | / | / |
| Levodopa and Benserazide Hydrochloride Tablet | 54 (71.1%) | −0.169 | 0.143 |
| Carbidopa and Levodopa-CR Tablet | 8 (10.5%) | −0.106 | 0.362 |
| Levodopa Tablet | 1 (1.3%) | 0.042 | 0.717 |
| Piribedil-SR Tablet | 27 (35.5%) | 0.759 | 0.450 |
| Pramipexole Dihydrochloride Tablet | 15 (19.7%) | −0.042 | 0.720 |
PD, Parkinson's disease; Beta value, adjusted regression coefficient; CR, controlled release; SR, sustained release.